The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011)

Melhem SolhFlorida Center for Cellular Therapy, Orlando, FL, USACorrespondence[email protected]

Kanti R. RaiLong Island Jewish Medical Center, New Hyde Park, NY, USA

Bercedis L. PetersonCancer and Leukemia Group B (CALGB) Statistical Center and Duke University, Durham, NC, USA

Jonathan E. KolitzNorth Shore University Hospital, Lake Success, NY, USA

Frederick R. AppelbaumFred Hutchinson Cancer Research Center, Seattle, WA, USA and Southwest Oncology Group (SWOG)

Martin S. TallmanMemorial Hospital, New York, NY, USA and Eastern Cooperative Oncology Group (ECOG)

Andrew BelchCross Cancer Institute, Edmonton, Alberta, Canada and National Cancer Institute-Canada Clinical Trials Group

Richard A. LarsonUniversity of Chicago, Chicago, IL, USA and CALGB, and

Vicki A. MorrisonVeterans Affairs Medical Center, Minneapolis, MN, USA; for the North American Intergroup

Your download is now in progress and you may close this window